

Medication Management in Patients Post-Myocardial Infarction

Cardiovascular (CV) disease remains the leading cause of death in the United States, with one American experiencing a myocardial infarction (MI) approximately every 40 seconds.¹ In addition to lifestyle modifications, the American College of Cardiology Foundation and American Heart Association guidelines for ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Acute Coronary Syndromes (NSTEMI-ACS) recommend specific therapies for secondary prevention of CV events.²⁻³ The following routine medical therapies are recommended indefinitely unless otherwise stated:

| Formulary Treatment Options for Management of Patients Post-MI ²⁻⁴ | | | |
|---|-------------------------------------|--|--|
| Drug Category | Generic Name (Brand Name) | Target Dose | Clinical Justification |
| Salicylates | aspirin (Ecotrin) | 81 mg once daily | <ul style="list-style-type: none"> Reduce risk of MI, stroke and CV death by reducing platelet aggregation. |
| P2Y ₁₂ inhibitors | clopidogrel (Plavix) | 75 mg once daily | <ul style="list-style-type: none"> Reduce thrombosis risk by preventing platelet aggregation. DAPT (P2Y₁₂ inhibitor in addition to aspirin) is recommended for up to one year. <ul style="list-style-type: none"> Continuation of DAPT beyond one year may be considered in patients undergoing stent implantation. Place in therapy in NSTEMI-ACS: <ul style="list-style-type: none"> Ticagrelor is preferred over clopidogrel in patients who undergo early invasive or ischemia-guided strategy. Prasugrel is preferred over clopidogrel in patients who undergo PCI and are not at high risk of bleeding. |
| | prasugrel (Effient) | 5–10 mg once daily | |
| | ticagrelor (Brilinta) | 90 mg twice daily | |
| Beta blockers | atenolol (Tenormin) | 100 mg once daily | <ul style="list-style-type: none"> Reduce mortality and morbidity by reducing cardiac mortality, sudden death and reinfarction. Bisoprolol, carvedilol or metoprolol succinate are preferred in patients with HF and systolic dysfunction. Treatment course: 3 years. Metoprolol tartrate twice daily can be switched to metoprolol succinate ER once daily with the same total daily dose. |
| | bisoprolol (Zebeta) | 10 mg once daily | |
| | carvedilol (Coreg) | 25 mg twice daily | |
| | metoprolol tartrate (Lopressor) | 100 mg twice daily | |
| | metoprolol succinate ER (Toprol XL) | 200 mg once daily | |
| ACE-i | benazepril (Lotensin) | 40 mg once daily | <ul style="list-style-type: none"> Reduce fatal and nonfatal major CV events by lowering preload and afterload through inhibition of the renin-angiotensin-aldosterone system. Consider ARB therapy if ACE-i intolerant. |
| | enalapril (Vasotec) | 40 mg once daily | |
| | lisinopril (Zestril) | 40 mg once daily | |
| ARB | irbesartan (Avapro) | 300 mg once daily | |
| | losartan (Cozaar) | 100 mg once daily | |
| | telmisartan (Micardis) | 80 mg once daily | |
| | valsartan (Diovan) | 160 mg twice daily | |
| Statins | atorvastatin (Lipitor) | 40–80 mg once daily | <ul style="list-style-type: none"> High-intensity statins reduce major ASCVD events in patients 75 years or younger. For patients over 75 years, a moderate- or high-intensity statin is recommended. |
| | rosuvastatin (Crestor) | 20–40 mg once daily | |
| Nitrates | nitroglycerin (Nitrostat) | 0.4 mg SL every five min. as needed for chest pain (up to three doses) | <ul style="list-style-type: none"> Reduce ischemic anginal symptoms as needed in patients with NSTEMI-ACS with recurrent ischemic pain. |

DAPT= dual antiplatelet therapy; PCI = percutaneous coronary intervention; HF = heart failure; HTN = hypertension; ACE-i = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; ASCVD = atherosclerotic cardiovascular disease; SL = sublingually

References

- Tsao C, Aday A, Almarazooq Z, et al. Heart Disease and Stroke Statistics – 2022 Update: A Report from the American Heart Association. *Circulation* 2022;145:e153–e639.
- O’Gara P, Kushner F, Ascheim D, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Circulation*. 2013;127:e362–e425.
- Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. *Circulation*. 2014;130:e344–e426.
- Grundy S, Stone N, Baley A, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol*. 2019;73(24):e285–e350.

Medi-Cal Rx Contract Drug List: <https://medi-calrx.dhcs.ca.gov/home/cdl/>

OneCare Formulary: www.caloptima.org/en/ForProviders/PharmacyInformation/OneCareMedicarePartD.aspx